TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Medical resources consumed due to hematological adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Clicking-Crepitus Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean maximum standardised uptake value (SUVmax) on PET-CT scanning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of VS-5584
Endpoint domain: Adverse events/effects
Primary endpoint: Whole-body and regional BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in the total wound count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in the surface area of patients treated vs patients on placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of treated patients that had more than 75% wound shrinkage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of paclitaxel liposome injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognostically Significant CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of Hypocalcemia within 24 hours after moderate-severe TBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Colonization of P. acnes in the dermis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Endothelial function assessed by flow-mediated dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma vascular cell adhesion molecule-1 (VCAM-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma intercellular adhesion molecule (ICAM-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sleep Disorder Identification Rates
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: breast cancer biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in perineal pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in childbirth comfort scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in perineal trauma scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological responses to stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective responses to stress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Biochemical improvement of diabetes (HbA1c < 6.5%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Doppler indices of middle cerebral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gefitinib plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With CTCAE Grade 3 or 4 Hematology Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence rate of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Salivary gland changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of pathologic complete response in DCIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in WOMAC Osteoarthritis Index Pain Score at the End of Treatment Period 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in WOMAC Osteoarthritis Index Pain Score at the End of Treatment Period 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hypercoagulability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Acute Kidney Injury (AKI) or requirement for RRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Frequency of adverse events of special interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Biological Signatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caesarean Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Acceptability of Intrapartum Ultrasound
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of Ultrasound Labour Parameters
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Organ transplant viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Occurrence of Primary Efficacy Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Occurrence of Major Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Time to loss of primary patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean number of micturitions per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage and severity of OHSS
Endpoint domain: Adverse events/effects
Primary endpoint: Psychotomimetic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal episodic memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Strength of subjective drug effect
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in lung dynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Antibody titer levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: improvement in social cognitive ability
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Time to first respiratory tract infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: rate of primary engraftment 50 days post SCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total incidence of overall acute GvHD (greater than or equal to grade 3)
Endpoint domain: Adverse events/effects
Primary endpoint: Pain and function (Short Form-36 Shoulder Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain and function (ASES Shoulder Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth Modulation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Metabolic Response rate (OMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Serious and Other (Non-Serious) Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Hair coverage of the targeted area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of vaccinia infection complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from baseline of Plasma Oxidized LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fatal and non-fatal cardiac events
Endpoint domain: Mortality/survival
Primary endpoint: number of inflammatory, non-inflammatory and total lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Disorder
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Rates of donor chimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of remission
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: NOL variation (delta NOL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Daily Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of missed working or school days
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Time from first exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of exacerbations including their durations and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Dose-Limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: 30-day postoperative infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in spirometric measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline in respiratory muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline in gas exchange measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in the MHI-17 global psychological distress subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Annualized Rate of Change in the API ADAD Composite Cognitive Test Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Annualized Rate of Change in the FCSRT Cueing Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum concentrations of endogenous estrogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum concentrations of endogenous androgens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Number of Headache Days Per Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thyroid-stimulating hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: success of continuing breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: amount of supplementation used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Combined Failure of Bacteriological Cure and Relapse Within One Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Patients With Grade 3 or 4 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in maximum phonation duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (INS-LIS 0-20h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (GIR 0-20h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fog Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of Daunorubicin Cytarabine liposomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bayley III cognitive composite score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Bayley III language composite score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Bayley III Expressive Language Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Bayley III Receptive Language Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Bayley III Motor Composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Teeth With Normal and Abnormal Pulp
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of feeding intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Muscle protein fractional synthetic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in smoking status from baseline to end of 8 week program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Smoking status at 3 months following end of 8 week program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite incidence of all complications within 30 days after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Speech comprehension scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Major birth defects
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Achieving None or Mild on the Severity of Crow's Feet Lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Women's opinion on alcoholism screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cmax, Tmax, AUCtau, AUCinf, T1/2, accumulation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of subjects following multiple dosing (adverse events, vital signs, telemetry, ECGs, physical examination, blood and urine tests)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Patients Who Are Willing to Participate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Patients Who Complete the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: change in biopsy conclusions (treatment success or not)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: presence of fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: presence of cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of moderate to severe hot flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking cessation rate biochemical verification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking cessation rate smartwatch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD during heat stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD during cold stimulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat oxidation (max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fat oxidation (min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence and Magnitude of Participants with Treatment-emergent hematology clinical abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence and Magnitude of Participants with Treatment-emergent chemistry abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes from baseline in respiratory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline of upper extremity function & structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality of decision making process
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants Recruited and Retained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to the Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Palatability of Supplement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in Proviral HIV-1 DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Acuity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma TNF-alpha concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Local progression-free survival at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Who Achieved EBS Remission at Week 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants Who Achieved EBS Remission at Week 58
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Aggression Levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of alterations in chordoma susceptibility genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in mean CTC cluster size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Achieving Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in baseline exercise test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for albuterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for budesonide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for albuterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for budesonide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of spike wave
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Optimal sensitivity and specificity of endometrial biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Infection percent after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative rate of vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in Worst-itching Visual Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subjective CLUE Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Corneal Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment related mortality at 1 year after myeloablative cord transplant
Endpoint domain: Mortality/survival
Primary endpoint: BAL Pepsin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in SIB total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CIBIC-plus total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: pain on post-operative day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Serious Adverse Events (SAEs) After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Creatinine Elevations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Successful completion of the ePainQ questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time From Surgery to First Ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to Surgery Recovery Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change of depression and anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Autonomic nervous system (ANS) function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Per Patient Referral Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough Forced Expiratory Volume in 1 second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cardiac repolarisation (QT, QTc interval)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MFM score change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CHOP-INTEND score change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Hammersmith score change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moviplate score change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grip strength change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of grade III-IV acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients achieving complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Natural History of SLE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of insufflation device related subcutaneous emphysema (SCE)
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of mHealth app
Endpoint domain: Life impact
Endpoint subdomain: Other resource use